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Abstract
The HIV/AIDS epidemic continues to be a critical public health issue in the United States, where an
estimated 1.2 million individuals live with HIV infection. Viral suppression is one of the primary public health
goals for People Living with HIV/AIDS (PLWHA). A crucial component of this goal involves adequate access
to health care, specifically anti-retroviral HIV medications. The enactment of the Affordable Care Act (ACA) in
2010 raised hopes for millions of PLWHA without access to health care coverage. High cost-sharing re-
quirements enacted by health plans place a financial burden on PLWHA who need ongoing access to these life-
saving medications. Plighted with poverty, Detroit, Michigan, is a center of attention for examining the financial
burden of HIV medications on PLWHA under the new health plans. From November 2014 to January 2015,
monthly out-of-pocket costs and medication utilization requirements for 31 HIV medications were examined for
the top 12 insurance carriers offering Qualified Health Plans on Michigan’s Health Insurance Marketplace
Exchange. The percentage of medications requiring quantity limits and prior authorization were calculated. The
average monthly out-of-pocket cost per person ranged from $12 to $614 per medication. Three insurance
carriers placed all 31 HIV medications on the highest cost-sharing tier, charging 50% coinsurance. High out-of-
pocket costs and medication utilization restrictions discourage PLWHA from enrolling in health plans and
threaten interrupted medication adherence, drug resistance, and increased risk of viral transmission. Health
plans inflicting high costs and medication restrictions violate provisions of the ACA and undermine health care
quality for PLWHA. (Population Health Management 2016;19:272–278)
Introduction
The HIV/AIDS epidemic continues to be a criticalpublic health issue in the United States. It is estimated
that nearly 1.2 million individuals in the United States were
infected with HIV in 2011.1 Of this total, 86% were diag-
nosed with the infection, yet only 40% were engaged in
medical care, and only 30% were virally suppressed.1 The
other 60% diagnosed with HIV who are not engaged in care
are at an increased risk of experiencing complications from
uncontrolled viral loads, such as increased vulnerability to
bacterial infections, as well as cardiovascular, liver, neuro-
pathic, and kidney problems.2 Individuals who cannot sup-
press their viral loads are also at increased risk of acquiring
AIDS and transmitting the virus to others.2,3,4 Viral load
suppression is one of the primary public health goals for
People Living with HIV/AIDS (PLWHA), and a high priority
for maintaining and ensuring a high quality of life and well-
being for these individuals.5,6 The US Centers for Disease
Control and Prevention (CDC) estimates that 76% of in-
dividuals who are in care achieve viral load suppression,
highlighting the importance of encouraging HIV-infected
individuals to get into care as soon as possible, and stay
in care.5
The importance of getting into care and staying in care
underscores the necessity of adequate health care coverage
for PLWHA.1,7 The enactment of the Patient Protection and
Affordable Care Act (PPACA), also known as the Afford-
able Care Act (ACA), in 2010 has promoted access to health
care coverage for millions of Americans who had no pre-
vious source of health care.7 The 2 most significant benefits
for individuals living with HIV/AIDS have been the op-
portunity to purchase private health insurance through state
marketplace insurance exchanges, and the ability to enroll
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without fear of denial of coverage, or annual limits on
benefits, related to a preexisting health condition or their
current health status.7 The health insurance exchanges offer
a variety of bronze, silver, and gold plans that represent
different cost-sharing requirements but must offer the same
core essential health benefits required by the ACA.8 The
availability of new private health plans and the elimination
of discriminatory insurance practices represent 2 major
hallmarks of the ACA with tremendous social, political, and
historical importance for PLWHA.
Despite the prohibition of discriminatory insurance prac-
tices under the ACA, recent concerns have been raised re-
garding the structuring of health care benefits by certain
insurance companies that impose excessive financial and
access restrictions to important health care services, in-
cluding medication acquisition.9 In May 2014, the AIDS
Institute and the National Health Law Program filed an of-
ficial complaint with the Office for Civil Rights in the United
States Department of Health and Human Services against 4
Florida insurers for engaging in insurance practices that ac-
tively discouraged PLWHA from enrolling in their plans.9
CoventryOne, Cigna, Humana, and Preferred Medical struc-
tured their drug formularies in a way such that all HIV/AIDS
medications were placed on the highest cost-sharing tier, and
also enacted medication restrictions such as prior authoriza-
tion and quantity limits.9 These restrictions can serve as bar-
riers to adequate access to anti-retroviral therapy (ART)
medications for PLWHA.9,10
Excessive high costs for HIV medications place a finan-
cial burden on PLWHA who need ongoing access to these
life-saving medications, and can discourage them from en-
rolling in health care plans.9 As it is estimated that 87% of
individuals in care in the United States with HIV between
the ages of 19–64 have incomes below 400% of the federal
poverty level, the issue of financial access to medications is
crucial to address.7 The relationship between socioeconomic
status (SES) and HIV is of critical public health concern, as
people with lower SES are disproportionately impacted by
HIV infection.11,12 Poverty and low SES are risk factors for
HIV infection, as people with inadequate access to socio-
economic resources may engage in riskier sexual practices
that can lead to HIV contraction.11,12,13 In particular, lack of
access to medical care heavily influences access to needed
medications and appropriate medication adherence.14 Poor
medication adherence can lead to reduced health outcomes
for PLWHA and an increase in drug resistant HIV strains
that can be transmitted to others.3,15,16
Because of the strong connection between poverty and
vulnerability to HIV infection, prodigious attention has been
focused on the HIV/AIDS epidemic in the impoverished city
of Detroit, Michigan, a region devastated by economic and
financial struggle in recent years. According to 2013 esti-
mates, Detroit has the highest HIV prevalence rate in Mi-
chigan, at 7040 per 100,000 individuals.17 Furthermore,
64% of individuals infected with HIV in Michigan reside
in Detroit at the time of diagnosis.17 There is also a dis-
proportionate impact of HIV on African American men in
Detroit, particularly among African American men who
have sex with men.17 This population has the highest HIV
prevalence rate in the state, and also the highest number of
PLWHA.6 Because of the high prevalence rate of HIV/
AIDS among underserved and vulnerable populations in
Detroit, the issue of financial access to comprehensive HIV
health care needs is a crucial one that needs to be addressed.
The Ryan White HIV/AIDS Program (RWHAP) has been
essential to filling the gaps in health care coverage for
PLWHA. The Ryan White legislation was passed by Con-
gress in 1990 to promote health care services for PLWHA
who have insufficient financial resources to obtain needed
medical care and support services for their HIV condition.18
The legislation was named in honor of a young boy named
Ryan White who was diagnosed with AIDS at the age of 13
after he underwent a blood transfusion procedure needed for
his hemophiliac condition. The RWHAP continues to serve
as a critical safety net for PLWHA who do not qualify for
expanded Medicaid programs or the federally facilitated
health insurance marketplace exchange (ACA marketplace
exchange).7,18 An individual living with HIV/AIDS may be
eligible for expanded Medicaid, also known as the Healthy
Michigan Plan, if he or she is at or below 133% of the
federal poverty level.19 However, if an individual living
with HIV/AIDS is not within these income requirements, he
or she would not be eligible for Medicaid and may proceed
to look for coverage through the marketplace exchange,
which does not have an income requirement. In order to be
eligible for the marketplace exchange, one must be a US
citizen living in the United States, not currently incarcer-
ated, and not have access to health insurance coverage
elsewhere.20 There are no income requirements in order to
be eligible for the marketplace, although financial assistance
is available for individuals who qualify. However, it is im-
portant to recognize that even among PLWHA who do
qualify for the health insurance marketplace exchange, the
Ryan White Programs play a crucial role in assisting with
the payment of prescription drug co-payments as well as
insurance plan premiums and deductibles charged by the
Qualified Health Plans (QHPs).
The lines delineating who is eligible for the marketplace
exchange and who is eligible for the Ryan White programs
are not always clear cut. In other words, it is possible for
PLWHA to obtain both exchange coverage and Ryan White
coverage. The ACA marketplace exchange offers financial
assistance in the form of premium tax credits for individu-
als within 100%–400% of the federal poverty level to help
lower monthly premium payments, and also cost-sharing
subsidies to reduce co-payments for doctor’s visits and pre-
scription drugs for individuals who are within 100%–250%
of the federal poverty level.7 However, despite these finan-
cial assistance programs offered by the ACA marketplace,
prescription drug co-payments, premiums, and deductibles
still may be a formidable barrier for low-income PLWHA.
For a 55-year old individual living with HIV/AIDS with an
annual income of $17,655 (150% of the federal poverty level)
in Detroit, Michigan, the monthly premium for a health plan
on the exchange may cost up to $345 per month. This is where
the Ryan White Program steps in to assist individuals with
these costs. The Ryan White Program consists of 5 different
programs (Parts A–F), which provide funding to multiple
types of entities such as state and local health departments,
research institutions, as well as community-based organiza-
tions.18 This funding is used to provide diverse health care
services to various populations of individuals living with HIV
(eg, all adults, pregnant women, infants, children, metro-
politan area residents).18 Each program within Ryan White
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may target a different population of PLWHA, and the in-
come eligibility requirements of the Ryan White Programs
may vary by state and program. In Michigan, with some
exceptions, the Ryan White Programs will cover individuals
living with HIV/AIDS who are at or below 450% of the
federal poverty level.
The Part B Program of the Ryan White Act is critical to
this discussion of affordable prescription HIV drug coverage
for PLWHA. This program provides funding for the State
AIDS Drug Assistance Programs for PLWHA who need
financial assistance paying for their HIV medication co-
payments, insurance plan premiums, or insurance plan de-
ductibles. In order to be eligible for the Ryan White-funded
Michigan Drug Assistance Program (MIDAP), a person
must provide proof of HIV status, must be a resident of
Michigan, and must be at or below 450% of the federal
poverty level.21 In some cases, eligible individuals also must
show that they have applied for public assistance programs
such as Medicaid and have either a pending or denial status.
This criterion is to ensure that Ryan White Funds are
utilized in a cost-effective way by targeting PLWHA who
truly have no other source of coverage to help cover the
costs of their medications. MIDAP may help pay for the
premiums, deductibles, and co-payments of medications
charged by Qualified Health Plans (QHPs) on the mar-
ketplace exchange. However, for low-income individu-
als living with HIV/AIDS who may not qualify for the
marketplace exchange (ie, undocumented citizens, self-
employed, individuals who do not qualify for Medicaid),
or any other type of health insurance, MIDAP can provide
‘‘full coverage’’ to these individuals and pay for the full
cost of their HIV medications in the absence of insur-
ance coverage. Moreover, other individuals who may al-
ready have health insurance through the marketplace may
qualify under MIDAP to receive co-payment, premium,
and deductible assistance. Undoubtedly, there is a great
deal of eligibility overlap between the exchanges and the
Ryan White programs, which ensures that low-income
PLWHA are not falling through the cracks and becoming
lost to care.
In Michigan, of the estimated 8809 individuals with HIV/
AIDS who are enrolled in the RWHAP, 75.9% have in-
comes below 100% of the federal poverty level.22 These
statistics point to the fact that financial access to HIV care
services poses a barrier for PLWHA. Financial barriers to
essential HIV medications in Michigan continue to be a
critical issue. Access to life-saving ART medications is
one of the most crucial components of appropriate health
care services for PLWHA.1,3 Adequate access to ART for
PLWHA is a top priority for Michigan’s Statewide Co-
ordinated Statement of Need and CDC’s strategic HIV
prevention plan.6,17 The prominent need for HIV Care ser-
vices in Michigan generally, and Detroit in particular, un-
derscores the importance of examining the impact of the
ACA in making health care more affordable for this popu-
lation of great need in Michigan. Because of the dearth of
studies examining the coverage of HIV/AIDS medications
on the drug formularies of QHPs on the Michigan Health
Insurance Marketplace Exchange, this article presents a first
of its kind cost comparison of the out-of-pocket costs of
HIV medications charged by 12 major insurance carriers in
Detroit, Michigan.
Methods
Between November 2014 and January 2015, the drug
formularies of 12 major insurance carriers offering silver
QHPs in Wayne County on the Michigan Health Insurance
Marketplace Exchange were analyzed. The following 12
carriers are the major health insurance companies offering
plans on the marketplace in the entire State of Michigan:
Priority Health, Blue Cross Blue Shield, Blue Care Network,
Health Alliance Plan (HAP), McLaren Health Plan, Total
Health Care USA Inc, Consumer’s Mutual of Michigan, As-
surant Health, United Healthcare, Humana, Harbor Health
Plan, and Molina Healthcare of Michigan. Forty-nine silver
QHPs are offered in Wayne County on the 2015 Michigan
Marketplace Exchange. The drug formularies were located on
the insurance companies’ Web sites. Using the drug formulary
criteria of the MIDAP, the author calculated the monthly
out-of-pocket cost per person charged by the insurance
carriers for each of the 31 ART HIV medications examined.
At the time this research was performed, the MIDAP for-
mulary covered 31 ART medications.
The 31 drugs examined were Abacavir (Ziagen), Abacavir/
lamivudine (Epzicom), Abacavir/lamivudine/zidovudine (Tri-
zivir), Atazanavir (Reyataz), Darunavir (Prezista), Delavirdine
(Rescriptor), Didanosine (Videx), Dolutegravir (Tivicay),
Efavirenz (Sustiva), Efavirenz/emtricitabine/tenofovir (Atri-
pla), Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild),
Emtricitabine(Emtriva), Emtricitabine/tenofovir (Truvada),
Emtricitabine/rilpivirine/tenofovir (Complera), Enfuvir-
tide (Fuzeon), Etravirine (Intelence), Fosamprenavir (Lexiva),
Indinavir (Crixivan), Lamivudine (Epivir), Lamivudine/
zidovudine (Combivir), Maraviroc (Selzentry), Nelfinavir
(Viracept), Nevirapine (Viramune), Raltegravir (Isentress),
Rilpiviring (Edurant), Ritonavir (Norvir), Saquinavir (In-
virase), Stavudine (Zerit), Tenofovir (Viread), Tipranavir
(Aptivus), and Zidovudine (Retrovir).23 The HIV medica-
tions are identified by their generic name, with corre-
sponding brand names in parentheses. The drug formularies
categorized medications according to tier level, which de-
termines whether a drug is a generic medication, a preferred
brand medication, a non-preferred brand medication, a
preferred specialty medication, or a non-preferred specialty
medication. The tier categorization dictates the cost-sharing
obligations for the medications. Although tier levels vary
slightly between insurance carriers, levels are usually cat-
egorized on 4 or 5 tier levels. A higher tier level generally
corresponds to a higher co-payment (co-pay) or coinsurance
cost for the medication. A co-pay is a fixed dollar amount
that a patient is obliged to pay each time a medical service is
obtained, whereas a coinsurance is a fixed percentage of the
total medical service bill that a patient is obliged to pay each
time a medical service is obtained. Generally speaking, a co-
pay is less expensive than coinsurance, because coinsurance
will increase as the cost of the medical service increases,
whereas a co-pay will always remain the same. Tier levels 3
and above were considered to be higher tier levels. Speci-
alty Drug Tier Levels (usually 4 or 5) were considered to be
the highest tier level.
The estimated retail cost of the drug was derived from
the PositivelyAware (PA) HIV Drug Guide.24 PA is a not-
for-profit HIV/AIDS treatment journal published by Test
Positive Aware Network, a not-for-profit AIDS Service
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Organization based in Chicago. The PA site has been used
as a trusted resource by various federally funded State Drug
Assistance Programs, such as Michigan and Illinois, as well
as nonprofit organizations such as the AIDS Foundation of
Chicago, to estimate monthly drug costs for clients on the
drug assistance programs and to assist with cost-effective
analyses in state program planning. Because insurance plans
offered on the marketplace are not always transparent about
the actual out-of-pocket costs for HIV medications, the PA
site acts as a trusted substitute in calculating estimated out-
of-pocket costs for expensive HIV medications. Hence, the
PA site was used in this research as the select resource for
estimating HIV drug costs.
Based on the PA drug guide’s estimated monthly retail
costs for the medications, the co-pay or coinsurance cost
charged by the health insurance plan was applied in order to
determine the estimated out-of-pocket cost per person per
month for the HIV medications examined. The co-pay or
coinsurance cost for each silver plan was obtained from the
Michigan Marketplace healthcare.gov. The average out-of-
pocket cost per person per month was calculated for all HIV
medications covered by each insurance carrier. The drug
formularies of each insurance carrier were analyzed to de-
termine the total number of covered HIV medications and
the number of HIV medications with utilization management
restrictions such as quantity limits and prior authorizations.
Numbers are displayed as percentages in Figures 1–5.
Results
Results found that the overall coverage of HIV medications
is extremely high among the 12 insurance carriers, ranging
from 90.3% coverage to 100% coverage. Humana, Harbor
Health Plan, United Healthcare, Consumer’s Mutual, Blue
Cross Blue Shield, Blue Care Network, McLaren Health Plan,
and Assurant Health covered 100% of HIV medications.
Priority Health and Molina covered 96.8% and HAP covered
90.3%. Because these are among the most prominent insur-
ance carriers in Michigan that offer Qualified Health Plans on
the marketplace exchange, it is reassuring to know that HIV
medication coverage on drug formularies is high.
Figure 1 illustrates the average out-of-pocket cost per
person per month charged by each insurance carrier for the
31 HIV medications examined. As illustrated by Figure 1,
Humana, Harbor Health Plan, and HAP charge the highest
out-of-pocket costs, ranging from $567 to $614 per person
per month per HIV medication. Blue Cross Blue Shield,
Blue Care Network, Priority Health, Assurant Health, and
United Healthcare charge lower average out-of-pocket costs
per person per month, ranging from $101 to $252. McLaren
Health Plan, Molina, Total Health Care, and Consumer’s
Mutual charge the lowest average out-of-pocket costs per
person per month. These results indicate the large discrep-
ancy in co-pay and coinsurance costs charged by insurance
carriers for the same HIV medications.
Figure 2 illustrates the percentage of HIV medications
placed on higher cost-sharing tier levels. Eleven of the 12
insurance carriers placed more than 1 HIV medication on
the higher cost-sharing tiers. Three of the 12 insurance
carriers placed all 31 HIV medications on higher tier levels.
Three of the 12 insurance carriers, Humana, HAP, and
Harbor Health Plan, placed every single HIV medication on
the highest (specialty) tier level, meaning that clients would
be paying the highest out-of-pocket cost for these medica-
tions. These 3 insurance carriers charge 50% coinsurance for
these HIV specialty drugs, the highest coinsurance charged
by any of the insurance carriers examined.
Figure 3 depicts the percentage of HIV drugs on the drug
formularies that require quantity limits by each insurance
carrier. Humana, Assurant Health, and Total Health Care
required quantity limits for all 31 HIV medications examined.
FIG. 1. The average out-of-pocket cost per person
charged by insurance carriers for HIV medications.
FIG. 2. The percentage of HIV drugs placed on higher tier
levels on the drug formulary of each insurance carrier.
FIG. 3. The percentage of HIV drugs with quantity limits
on the drug formulary of each insurance carrier.
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Eleven of the 12 insurance carriers required quantity limits for
more than 1 covered HIV medication. Five of the 12 insurance
carriers required quantity limits for more than half of covered
HIV medications on their formularies.
Figure 4 shows the percentage of HIV medications re-
quiring prior authorizations by the insurance carriers. Six of
the 12 insurance carriers require prior authorizations for
some of the HIV medications covered on their formularies.
Figure 5 shows the coinsurance charged by each insurance
carrier for specialty HIV drugs. Three insurance carriers
(Humana, HAP, Harbor Health Plan) all charged 50% co-
insurance for HIV drugs categorized under the specialty tier.
Total Health Care, McLaren, and Assurant Health were
excluded as they did not charge coinsurance for their spe-
cialty medications.
Discussion
Two of the main tenets of the ACA with tremendous
significance for PLWHA are improved access to affordable
health care coverage and the elimination of discriminatory
insurance practices toward people with preexisting condi-
tions and other significant health issues.7 These results show
that although overall coverage of HIV medications is high
on the drug formularies examined, the high out-of-pocket
costs charged by some insurance carriers may still pose a
serious financial barrier to socioeconomically deprived
PLWHA living in the Detroit Metropolitan Area. As 75.9%
of PLWHA in RWHAP care in Michigan have household
incomes below 100% of the federal poverty level, the high
out-of-pocket costs for HIV medication acquisition un-
doubtedly serve as a barrier to adequate health care access.22
To help buffer the costs of health care coverage and increase
incentives for enrollment of financially deprived individuals,
the ACA offers premium tax credits for individuals with
incomes within 100%–400% of the federal poverty level as
well as cost-sharing subsidies to individuals with incomes
within 100%–250% of the federal poverty level who enroll
in silver plans.7
Despite these subsidies, the results of this study demon-
strate that the out-of-pocket costs for HIV medications may
still pose a serious financial barrier for socioeconomically
deprived PLWHA. As PLWHA are often required to take
multiple HIV medications or combined pills as part of their
treatment regimen, they may be spending more than half of
their monthly income on just HIV medications. According
to Jonathan Cohn, MD, MS (oral communication, August
2015), Director at Wayne State University’s Adult HIV/
AIDS program located in Detroit, Michigan, the state’s
largest institution providing health care services to PLWHA,
the HIV drugs Stribild and Complera are some of the most
common single tablet regiments taken by PLWHA. These 2
HIV drugs are categorized as combination Nucleoside/
Nucleotide Reverse Transcriptase Inhibitors (NNRTIs) and
Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs),
also referred to as NNRTI/NRTI combination. Combined,
single-tablet pill regimens have been adopted as the pre-
ferred form of HIV medication intake by many PLWHA and
infectious disease providers, as they have been studied to
reduce pill burden and encourage medication adherence.25
According to PA, the average cost for Stribild and Complera
per month is $2463.37 each. For an individual living with
HIV/AIDS under a Humana insurance plan, which charges a
coinsurance of 50% as found by the current research, the
total out-of-pocket cost for an individual on Stribild or
Complera would be about $1231.69 per month. For an in-
dividual with an income of 150% of the FPL, making about
$1471.25 a month, an average monthly cost of $1231.69 for
1 HIV medication would represent about 84% of their
monthly income. That is just the beginning of their expen-
ditures. In addition to covering the costs of their necessary
life-saving medications, PLWHA also must cover the costs
of needed laboratory tests, medical appointment visits, case
management services, dental care needs, and everyday ex-
penses such as transportation, housing, and nutrition.26 For
an individual living with HIV/AIDS with an income at or
below 150% of the federal poverty level, the monthly costs
of their medications are grossly disproportionate in the
scope of other needed living expenses.
Despite the promise of expanded insurance coverage
under the ACA, the cost-sharing fees for these HIV medi-
cations are undoubtedly prohibitive under many health plans
offered on the marketplace exchange. Higher cost sharing
for HIV medications may inhibit PLWHA from obtaining
their medications in a timely manner. The implications of
this may be profound, as interrupted medication adherence
may increase the risk of developing drug resistance, trans-
mitting the virus to others, and even death.1,3,10,27,28 The
FIG. 4. The percentage of HIV medications that require
prior authorization by insurance carrier.
FIG. 5. The coinsurance charged for specialty drug tier.
Total Health Care, McLaren, and Assurant Health were
excluded as they did not charge coinsurance for their spe-
cialty medications.
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results of the current study demonstrate that many of the
insurance carriers imposed utilization management restric-
tions for covered HIV medications. Utilization management
restrictions such as prior authorization may reduce acces-
sibility to treatment by increasing the likelihood that pa-
tients experience a delay in receipt of their medications,
leading to an interruption in their medication regimen.10
Continuous access and adherence to HIV medications are
crucial components for achieving the goal of viral load
suppression and improving health outcomes among PLWHA.1
Even short periods of interrupted or inadequate care may
drastically increase mortality risk among PLWHA.27
Targeting PLWHA with excessive utilization manage-
ment requirements and exorbitant out-of-pocket costs for
needed HIV medications also has the effect of discouraging
PLWHA from enrolling in health insurance, which represents
a violation of the ACA.9 42 USC Section 18031(c)(1)(a) states
that health plans offered on the marketplace exchange cannot
‘‘.employ marketing practices or benefit designs that have
the effect of discouraging the enrollment in such plan by
individuals with significant health needs.’’9,29 Categorizing
HIV medications on higher tier levels that require higher
cost sharing and imposing prior authorization and quantity
limits certainly constitute discouragement of PLWHA from
enrolling in QHPs.9
These issues all point to the potential unanticipated con-
sequences of the ACA for PLWHA. In addition to the dis-
ruptions in medication adherence and access posed by high
out-of-pocket costs and utilization management require-
ments of QHPs, difficulties in accessing and understanding
drug formularies and cost-sharing obligations highlight the
need to hold health insurance companies accountable for
transparency of their drug formularies.
It is important to comment on the difficulty of locating the
correct drug formularies. As this study found, links to drug
formularies on the Michigan marketplace exchange often
led to the home page of the insurance company instead of
directly to the formulary. Therefore, considerable extra time
and effort were required in order to search for the drug
formulary from that site. On average, the drug formulary
documents were 178 pages in length. Therefore, considerable
time and effort to review and locate the necessary HIV
medications was required. Moreover, locating the drug for-
mularies required access to a computer and adequate Internet
technology skills, which may be a barrier for socioeconom-
ically deprived PLWHA in cities such as Detroit who may
not have the resources to access a computer or the literacy
skills to analyze a drug formulary. Low SES is a risk factor
for poor health literacy skills.30 It is estimated that 47% of
adults in Detroit are considered functionally illiterate.31–33
This means that these adults have poor reading, speaking, and
writing skills. Individuals with low health literacy skills are
more likely to have poor adherence to their medication reg-
imen, poor comprehension of drug warning labels, and
decreased involvement in health promoting behaviors.34,35
Kalichman et al (2005) found poorer medication adherence
and more adverse health outcomes among people living
with HIV/AIDS who had lower health literacy skills.36
Undoubtedly, the tedious format in which some drug for-
mularies are provided may serve as a large barrier to care
and medication adherence for individuals of lower health
literacy residing in Detroit. Future efforts need to be made
on the part of insurance carriers to break down information
regarding drug coverage and drug costs in a manner that can
better facilitate informed decision making and insurance plan
selection among individuals with diverse health literacy skills.
Although the corresponding tier levels were displayed for
each medication on the drug formularies, the monthly out-
of-pocket costs were not made available. This is a signifi-
cant shortcoming in the current approach, as it prevents
PLWHA from gaining an understanding of what their esti-
mated cost-sharing obligation will be. These asymmetries
show that adequate health literacy skills and access to a
computer are needed for enhanced understanding of health
benefits and services offered by QHPs on the marketplace
exchange. With a majority of HIV/AIDS cases dispropor-
tionately distributed in the Detroit Metropolitan Area, en-
suring that vulnerable PLWHA not only have financial
access to life-saving medications, but also clear and com-
prehensive information about what health care benefits and
services are included in their QHPs, is critical to maintain-
ing and enhancing quality of life for PLWHA in Michigan.
These findings suggest that the assurance of providing
PLWHA with adequate and clear information about the
covered health benefits and cost-sharing obligations for
medications is crucial to informed decision making and
selection of a plan that best meets one’s health care needs.
These findings also suggest that continuous analysis and
monitoring of drug formularies is necessary to ensure that
insurance company practices are consistent with the legal
requirements of the ACA and to hold them accountable for
insurance benefit designs that take advantage of vulnerable
populations like PLWHA.
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